Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. announced a consolidation of its shares following a synthetic share repurchase plan approved by shareholders in June 2024. As part of the transaction, every 36 QIAGEN shares were consolidated into 35, impacting the holdings of Manager Roland Sackers, whose shares were adjusted accordingly. This move is likely aimed at optimizing the company’s capital structure and enhancing shareholder value, reflecting QIAGEN’s strategic financial management.
More about Qiagen
QIAGEN N.V. is a prominent player in the biotechnology industry, specializing in providing a wide array of products, including sample and assay technologies for molecular diagnostics, applied testing, academic, and pharmaceutical research. The company focuses on enabling customers to gain valuable molecular insights, which are crucial for various applications in healthcare and scientific research.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.
